详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

ISG20 promotes local tumor immunity and contributes to poor survival in human glioma

文献详情

资源类型：

收录情况： ◇ SCIE

作者：

机构： [a]Department of Neurosurgery, the First Hospital of China Medical University, Shenyang, China [b]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China [c]Chinese Glioma Genome Atlas network, Beijing, China

出处：

DOI：

ISSN：

关键词： ISG20 IDH mutation glioma prognosis innate immune response adaptive immune response chemokines PD1/PD-L1 CTLA4 RNA-seq

摘要：

Recent evidence has confirmed that a mutation of the isocitrate dehydrogenase (IDH) gene occurs early in gliomagenesis and contributes to suppressed immunity. The present study aimed to determine the candidate genes associated with IDH mutation status that could serve as biomarkers of immune suppression for improved prognosis prediction. Clinical information and RNA-seq gene expression data were collected for 932 glioma samples from the CGGA and TCGA databases, and differentially expressed genes in both lower-grade glioma (LGG) and glioblastoma (GBM) samples were identified according to IDH mutation status. Only one gene, interferon-stimulated exonuclease gene 20 (ISG20), with reduced expression in IDH mutant tumors, demonstrated significant prognostic value. ISG20 expression level significantly increased with increasing tumor grade, and its high expression was associated with a poor clinical outcome. Moreover, increased ISG20 expression was associated with increased infiltration of monocyte-derived macrophages and neutrophils, and suppressed adaptive immune response. ISG20 expression was also positively correlated with PD-1, PD-L1, and CTLA4 expression, along with the levels of several chemokines. We conclude that ISG20 is a useful biomarker to identify IDH-mediated immune processes in glioma and may serve as a potential therapeutic target.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 1 区

医学

小类 | 2 区免疫学 2 区肿瘤学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区免疫学 2 区肿瘤学

JCR分区：

出版当年[2017]版：

Q1 IMMUNOLOGY Q1 ONCOLOGY

最新[2023]版：

Q1 IMMUNOLOGY Q1 ONCOLOGY

影响因子： 6.5 最新[2023版] 7.2 最新五年平均 5.503 出版当年[2017版] 5.935 出版当年五年平均 7.719 出版前一年[2016版] 5.333 出版后一年[2018版]

第一作者：

第一作者机构： [a]Department of Neurosurgery, the First Hospital of China Medical University, Shenyang, China

通讯作者：

通讯机构： [a]Department of Neurosurgery, the First Hospital of China Medical University, Shenyang, China [*1]Department of Neurosurgery, the First Hospital of China Medical University, No. 155 Nanjingbei Street, Heping District, Shenyang 110001, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Innate immune response to influenza virus [2]IDH-1(R132H) mutation status in diffuse glioma patients: implications for classification [3]Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas. [4]Combining Bulk RNA-seq and scRNA-seq data to identify RNA m5C methyltransferases NSUN1: a rising star as a biomarker for cancer diagnosis, prognosis and therapy [5]A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma [6]Enolase-phosphatase 1 acts as an oncogenic driver in glioma. [7]MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status [8]MEGF10, A GLIOMA SURVIVAL ASSOCIATED MOLECULAR SIGNATURE PREDICTS IDH MUTATION STATUS [9]Methylation associated genes contribute to the favorable prognosis of gliomas with isocitrate dehydrogenase 1 mutation [10]Molecular and clinical characterization o PTPN2 expression from RNA-seq data of 996 brain gliomas